Amgen (AMGN) Competitors $272.72 -2.29 (-0.83%) As of 12:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMGN vs. GILD, VRTX, REGN, ALNY, BIIB, UTHR, EXEL, INCY, NBIX, and BMRNShould you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Exelixis (EXEL), Incyte (INCY), Neurocrine Biosciences (NBIX), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry. Amgen vs. Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Exelixis Incyte Neurocrine Biosciences BioMarin Pharmaceutical Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Does the media favor GILD or AMGN? In the previous week, Gilead Sciences had 5 more articles in the media than Amgen. MarketBeat recorded 44 mentions for Gilead Sciences and 39 mentions for Amgen. Gilead Sciences' average media sentiment score of 1.29 beat Amgen's score of 1.27 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 35 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Amgen 25 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, GILD or AMGN? Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGilead Sciences$28.74B4.72$480M$4.7522.97Amgen$34.13B4.33$4.09B$10.9625.09 Do analysts recommend GILD or AMGN? Gilead Sciences presently has a consensus price target of $110.55, suggesting a potential upside of 1.32%. Amgen has a consensus price target of $309.22, suggesting a potential upside of 12.44%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gilead Sciences 0 Sell rating(s) 9 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.78Amgen 2 Sell rating(s) 12 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.38 Is GILD or AMGN a better dividend stock? Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.9%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.5%. Gilead Sciences pays out 66.5% of its earnings in the form of a dividend. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has increased its dividend for 10 consecutive years and Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Which has more volatility and risk, GILD or AMGN? Gilead Sciences has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Does the MarketBeat Community prefer GILD or AMGN? Gilead Sciences received 926 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.86% of users gave Gilead Sciences an outperform vote while only 71.71% of users gave Amgen an outperform vote. CompanyUnderperformOutperformGilead SciencesOutperform Votes248576.86% Underperform Votes74823.14% AmgenOutperform Votes155971.71% Underperform Votes61528.29% Is GILD or AMGN more profitable? Amgen has a net margin of 12.24% compared to Gilead Sciences' net margin of 1.67%. Amgen's return on equity of 176.32% beat Gilead Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Gilead Sciences1.67% 31.63% 10.38% Amgen 12.24%176.32%11.71% Do insiders and institutionals believe in GILD or AMGN? 83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.8% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryGilead Sciences and Amgen tied by winning 11 of the 22 factors compared between the two stocks. Get Amgen News Delivered to You Automatically Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMGN vs. The Competition Export to ExcelMetricAmgenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$147.87B$2.97B$5.43B$8.48BDividend Yield3.63%1.72%5.22%4.11%P/E Ratio36.4331.5826.8220.05Price / Sales4.33414.63393.28116.44Price / Cash9.98168.6838.2534.62Price / Book25.163.376.874.61Net Income$4.09B-$72.17M$3.22B$248.19M7 Day Performance4.85%18.10%6.81%2.97%1 Month Performance0.49%20.85%13.71%16.58%1 Year Performance-12.65%-24.45%18.30%8.16% Amgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMGNAmgen4.6121 of 5 stars$272.72-0.8%$309.22+13.4%-12.6%$146.54B$34.13B36.1025,200Positive NewsAnalyst UpgradeGILDGilead Sciences4.6877 of 5 stars$105.32+2.8%$110.55+5.0%+60.7%$131.01B$28.74B284.6517,000Positive NewsAnalyst ForecastOptions VolumeVRTXVertex Pharmaceuticals4.6567 of 5 stars$438.640.0%$515.04+17.4%+0.3%$112.64B$11.10B-199.384,800Positive NewsREGNRegeneron Pharmaceuticals4.8223 of 5 stars$593.96-0.1%$890.60+49.9%-37.7%$64.13B$14.09B15.5211,900News CoveragePositive NewsDividend AnnouncementGap UpALNYAlnylam Pharmaceuticals3.6972 of 5 stars$291.12+2.0%$319.17+9.6%+94.1%$37.96B$2.35B-134.162,000Positive NewsBIIBBiogen4.9107 of 5 stars$128.27+2.1%$191.30+49.1%-43.6%$18.80B$9.82B11.468,720Positive NewsAnalyst RevisionUTHRUnited Therapeutics4.9819 of 5 stars$304.18-0.4%$392.00+28.9%+12.7%$13.72B$2.99B13.36980Positive NewsEXELExelixis4.0647 of 5 stars$44.64-1.7%$38.94-12.8%+110.6%$12.30B$2.17B25.221,220INCYIncyte4.8904 of 5 stars$63.37+0.1%$73.53+16.0%+14.2%$12.27B$4.41B234.712,320Positive NewsNBIXNeurocrine Biosciences4.9297 of 5 stars$122.31+1.1%$162.00+32.5%-13.2%$12.10B$2.41B37.181,200Positive NewsBMRNBioMarin Pharmaceutical4.9841 of 5 stars$59.23-0.1%$93.45+57.8%-22.2%$11.36B$2.95B26.923,080News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors EXEL Competitors INCY Competitors NBIX Competitors BMRN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMGN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
